Polpharma Biologics will retain full responsibility for developing and manufacturing the biosimilar candidate.
Apertura has entered a cooperative research and development agreement (CRADA) with various NIH institutes for a gene therapy ...
Morning Overview on MSN
A one-time CRISPR infusion cut hereditary swelling attacks by 87% in a first-ever trial
People living with hereditary angioedema, a rare genetic condition that triggers unpredictable and sometimes life-threatening ...
SAN DIEGO, US - Media OutReach Newswire - 9 July 2026 - Sapu Nano (US) LLC, a clinical-stage biotechnology company developing the proprietary Deciparticle™ nanomedicine platform, today announced that ...
Editor’s Pick: Retrospective Cohort Study of Long-Term Outcomes Associated with Severe Hyponatraemia
Hyponatraemia is the most common electrolyte abnormality among hospital inpatients, with clinical manifestations ranging from ...
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances T ...
StockStory.org on MSN
2 reasons to like HALO and 1 to stay skeptical
Halozyme Therapeutics trades at $78.57 and has moved in lockstep with the market. Its shares have returned 8.5% over the last ...
Overall, our findings demonstrate evidence of possible benefit in using high-dose vitamin C in the management of trauma ...
Benghazi’s Medical Industrial City is in the planning stages of building an international standard intravenous solution ...
A four-month-old baby died at a Nottingham hospital after "omissions of care" prompted concerns from her bereaved parents.
The biohacking therapy has attracted devotees from Bella Hadid to the Red Hot Chili Peppers. After more than a decade away, I ...
Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results